What General Genomics Inc. does

General Genomics Inc. is a privately held, Service-Disabled Veteran-Owned Small Business founded in 2020 and headquartered in Oklahoma City, with a wholly-owned subsidiary (General Genomics AI / GGAI) in Fort Worth, TX. The company develops AI/ML-powered bioinformatics software that combines proprietary machine learning models, large language models, predictive analytics, and synthetic data generation to analyze biological and man-made systems for government and commercial clients. Its product portfolio centers on three core platforms: Curo46™, an AI analytics platform for predictive health risk management, biosecurity threat assessment, and operational readiness; CuroSygnal, an explainable AI clinical decision support tool deployed in skilled nursing and post-acute care to surface return-to-hospital risk 3-14 days in advance; and SYN46™, which generates virtual patient models and downloadable de-identified datasets for privacy-compliant research and analytics. The company also offers EdTech and professional development training, a forthcoming Data Portal for synthetic data distribution, custom informatics solutions, and NAICS-aligned federal procurement services.

The firm pursues a direct enterprise sales motion targeting federal, state, and local government agencies (across DOD, HHS, DHS, Intel Community, USDA, FDA, and NASA) alongside commercial customers in healthcare providers, pharmaceuticals, insurance, sports medicine, and academic research. It relies on SDVOSB set-aside procurement advantages, NAICS code alignment, and compliance postures covering HIPAA, GDPR, and FDA 21 CFR Part 11 (clinical decision support exemption). CuroSygnal is natively integrated with the MatrixCare EHR and supports Microsoft single sign-on.

General Genomics generates revenue through platform licensing and subscriptions (Curo46™, CuroSygnal), synthetic and de-identified data products (SYN46™, forthcoming Data Portal), and professional services including custom AI/ML integration and workforce training. The company has raised approximately $4.95M across three funding rounds (2020, 2021, May 2024), holds one granted U.S. patent plus two pending patents on ML-driven disease prediction and treatment recommendation, and operates with an 11-50 employee team led by CEO & Founder AJ Rosenthal, COO & VP of Growth & EdTech Dr. Chris Naler (Col. USMC Ret.), and Director of Machine Learning Dr. Shannon Schlueter.

Name

General Genomics Inc.

Legal name

General Genomics, Inc.

Website

https://ggenomics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

AI/ML Bioinformatics Software

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Population Genomics & Preventive Precision Health Programs (HLAAANAL)

Keywords

• Predictive analytics
• Synthetic data
• Bioinformatics platforms
• Clinical decision support
• Genomic risk prediction

Headquarters

HQ city

Oklahoma City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AI/ML Platform Licensing and Subscriptions: Revenue generated from licensing proprietary AI platforms including Curo46™ and CuroSygnal to government and commercial clients. Solutions are tailored to organization-specific needs with custom implementation and ongoing support.
2. Synthetic and De-identified Data Products: Revenue from providing synthetic data (SYN46™) and de-identified datasets through the Data Portal for healthcare, research, and commercial applications.
3. Professional Services and Consulting: Custom AI/ML integration, workflow optimization, and professional development training services. Includes sector-specific training programs for government and commercial sectors.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

General Genomics develops and licenses AI/ML-powered bioinformatics platforms—Curo46™, CuroSygnal, and SYN46™—that combine proprietary genomic datasets, machine learning models, and large language models to deliver predictive analytics, return-to-hospital risk scoring, synthetic patient data generation, and decision-support insights for government agencies and commercial healthcare and pharmaceutical organizations. The platforms address disease susceptibility prediction, biosecurity threat assessment, and supply chain risk management with HIPAA, GDPR, and FDA 21 CFR Part 11 compliance built in.

Product overview

General Genomics Inc. offers a platform-plus-modules architecture centered on three core products: Curo46™ (AI-powered analytics platform), CuroSygnal (explainable AI clinical decision support), and SYN46™ (synthetic data/virtual patient models). These are complemented by specialized solutions including EdTech training programs, a Data Portal for synthetic data access, Custom Data Solutions, and NAICS code services. The platform serves both government (national security, public health, bioinformatics) and commercial (pharmaceuticals, insurance, research, sports medicine) sectors with AI/ML-driven predictive analytics, data governance, and bioinformatics solutions.

Differentiator

Problem solved

Functional benefit

Brands

• Curo46™: AI-powered platform designed to drive innovation in bioscience and data solutions, providing predictive health risk management, supply chain optimization, and advanced cybersecurity measures.
• CuroSygnal
• SYN46™
• General Genomics AI (GGAI)

Products and services

• Curo46™ Flagship AI/ML analytics platform that uses proprietary genomic and biological datasets plus LLMs to deliver predictive analytics, real-time dashboards, and actionable insights for disease detection, biosecurity threat assessment, supply chain risk management, and operational readiness across government and commercial clients.
• CuroSygnal Explainable AI clinical decision-support platform for skilled nursing and post-acute care teams that surfaces residents with elevated return-to-hospital risk 3-14 days in advance, featuring Hot Rack ranked patient queues, trend forecasting, and feature-level explainability. Native to MatrixCare EHR with Microsoft SSO authentication.
• SYN46™ Synthetic data solution that generates virtual patient models and downloadable datasets simulating individual health trajectories for disease prediction, preparedness, and privacy-compliant research and analytics across healthcare, government, and bioinformatics sectors.
• EdTech and Professional Development Training and workforce development services offering AI/ML integration workshops, custom training programs, and sector-specific professional development for government and commercial professionals.
• Data Portal Secure, compliant data portal providing access to synthetic and de-identified datasets, enabling businesses to request tailored data solutions across healthcare, government, and bioinformatics sectors.
• Custom Data Solutions Tailored data solutions combining advanced analytics, machine learning, and custom tools to optimize workflows, improve data accuracy, and predict outcomes for pharmaceuticals, insurance, and research organizations.
• De-Identified Data Safeguarded de-identified data solutions that maximize data usability for advanced research and analytics while protecting privacy compliance, enabling secure sharing and analysis across industries.

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ClosedLoop.ai: Healthcare-focused AI/ML predictive analytics platform that builds risk models (including hospital readmission) for payers, providers, and ACOs. Closest direct competitor to General Genomics on the predictive-health risk and post-acute analytics side of the business.
• Syntegra: Provider of synthetic healthcare data derived from real patient records for privacy-preserving research and analytics. Directly comparable to General Genomics' SYN46 synthetic data product and Data Portal offering.
• MDClone: Synthetic de-identified healthcare data platform used by health systems, payers, and life sciences companies for analytics and research. Overlaps with General Genomics' SYN46 and de-identified data products for healthcare and pharma use cases.

Broad incumbents

• Tempus AI: Large AI-powered precision medicine company combining genomic sequencing, multi-omics, and clinical data for oncology and broader healthcare. Broad incumbent in AI genomics and predictive analytics that competes with General Genomics' Curo46 platform at much larger scale.
• Komodo Health: Healthcare intelligence platform using AI over de-identified patient data for life sciences, payers, and providers. Broader incumbent in healthcare AI/data analytics overlapping with General Genomics' predictive and synthetic-data use cases.
• Owkin: AI-for-biology company building federated learning and multimodal models for pharma research and clinical trials. Comparable to General Genomics' bioinformatics and pharma R&D offerings at a more established scale.
• Aetion: Real-world evidence analytics platform for biopharma, regulators, and payers, leveraging de-identified patient data. Comparable to General Genomics' commercial-sector analytics and de-identified data products serving pharma and insurance.
• Health Catalyst: Healthcare data and analytics platform serving health systems with population health, risk, and operational analytics. Broad incumbent overlapping with General Genomics' healthcare and government analytics offerings.

Emerging players

• LeanTaaS: AI/ML-based operational analytics for hospitals and health systems, including capacity and patient-flow optimization. Adjacent to General Genomics' predictive analytics, with overlap on health system buyer personas.

Others

• Datavant: Healthcare data connectivity and de-identification infrastructure that links records across providers, payers, and life sciences. Enabling/ecosystem peer to General Genomics' synthetic and de-identified data strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/generalgenomics
• LinkedInlinkedin.com/company/generalgenomics
• Instagraminstagram.com/generalgenomics
• Xx.com/ggenomics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about General Genomics Inc.